SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Micromet Inc (MITI)
MITI 0.0955-6.4%Dec 9 3:02 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Arthur Radley7/11/2011 3:32:31 PM
   of 196
 
Needham & Company Reiterates a 'Buy' on Micromet (MITI); Signs BiTE Agreement with Another Brand Name Collaborator with Robust Terms

11:24 am ET 07/11/2011 - Street Insider

Needham & Company reiterates a 'Buy' on Micromet (NASDAQ: MITI), PT $13.Needham analyst says, "This morning, Micromet announced a new collaboration for its BiTE platform technology with Amgen (Nasdaq: AMGN) (N/R) focusing on three undisclosed solid tumor targets. This agreement includes an initial upfront payment of 10 million for the first antibody target: total milestones may reach 695 million plus double-digit royalties and development cost reimbursement (Amgen pays R&D costs)." "We favor this agreement for three reasons: (1) the deal terms are robust, given our understanding that the programs represent new targets brought forth by Amgen and thus are in discovery research testing; (2) this agreement adds another brand name to Micromet s list of collaborators, and (3) we note the focus on solid tumors, an area of major upside given Micromet s promising data (75% CR rate in a Phase 2 trial of relapsed/refractory adult ALL patients as reported at the recent EHA Meeting) in liquid tumors." For more ratings news on Micromet click here and for the rating history of Micromet click here. Shares of Micromet closed at $5.76 yesterday, with a 52 week range of $4.75-$8.63.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext